PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Churg-Strauss syndrome

Drugs in development · updated 30 October 2026

Churg-Strauss syndrome: drugs in development

Rare diseasePrevalence 1-9 / 100 000 according to Orphanet · ORPHA:183

As of 30 October 2026 there are 8 active clinical trials (recruiting or ongoing, phases I–III) on 7 drugs for churg-Strauss syndrome. 3 are experimental, that is not yet approved in the United States.

8Active trials
3Experimental drugs
1Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
SHR-1703II–III1NCT05979051
NS-229II1NCT06046222
PovetaciceptI–II1NCT05732402

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
BenralizumabFasenra®III3NCT06512883
MepolizumabNucala®, Bosatria®II–III3NCT05979051
DepemokimabExdensur®III1NCT05263934
TezepelumabTezspireII1NCT06230354

Sorted by most advanced phase and number of active trials.

All 7 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D015267 “Churg-Strauss Syndrome”. Prevalence: Orphanet.

ItalianoFrançaisDeutsch